Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment

ConclusionThese findings demonstrate tolerability and successful self-administration of Ig20Gly in PIDD, including elderly patients and patients starting IGRT de novo.

http://link.springer.com/10.1007/s10875-023-01436-4

Source: Journal of Clinical Immunology - February 21, 2023 Category: Allergy & Immunology Source Type: research